Melatonin Easy Dissolve
|
|
- Peregrine Wilcox
- 7 years ago
- Views:
Transcription
1 webber naturals NPN: Class: Hormone Melatonin Easy Dissolve Ingredients (alphabetical) Medicinal: Melatonin Non-medicinal: Croscarmellose sodium, lactose monohydrate, microcrystalline cellulose, peppermint flavour, vegetable grade magnesium stearate Allergens Corn, dairy Source Synthesized Uses Sublingual melatonin is used to improve the quality of sleep in those with an age-relateddecline in melatonin [Jellin et al, 2004]. Sublingual melatonin is used to reestablish a normal circadian sleep rhythm in those suffering from disturbed sleep patterns relating to jet lag, shift-work, and in delayed sleep phase syndrome (DSPS) [Jellin et al, 2004]. Sublingual melatonin is used in circadian rhythm disorders in the blind, in sleep disturbances relating to depression, Alzheimer s Disease, and relating to benzodiazepine and nicotine withdrawal [Jellin et al, 2004]. Recommended Amount Use 1 tablet sublingually at bedtime, or as directed by a physician. Use up to 3 tablets daily. The sublingual route compared to the oral route is expected to provide a more consistent bioavailability of melatonin. Early pharmacokinetic studies indicated that 30 to 60 percent of an oral dose is metabolized during the first pass in the liver [Lane & Moss, 1985]. Furthermore, absorption of melatonin via the gut is thought to be highly variable [Kovacs et al, 2000]. One investigation using 80 mg in gelatin capsule form administered to 5 young males demonstrated a 25-fold variation in the concentration-time curve [350 to 10,000 times higher than the usual nocturnal peak] [Waldhauser et al, 1984]. Melatonin in Children Since melatonin is an endogenous human neuro-hormone, its use in children is expected to be safe, and effective on an empirical basis in children suffering from sleep problems associated with a variety of reasons [Coppola, 2004] [Forrester, 2004] [Gupta, 2004] [Gupta et al, 2004] [Phillips & Appleton, 2004]. In most cases of childhood chronic insomnia, a physician should be consulted for guidance in melatonin dosing and administration timing. Dosing and timing information can be suggested from two studies. In the Smits et. al. study [Smits et al, 2001], 40 children between 6 and 12 years old who suffered more than one year from chronic sleep onset insomnia were treated with 5 mg at 6:00 pm daily. Mild headache occurred in two children only during the first two days of melatonin treatment. Eighteen months after the start of the trial, in 13 of 38 children who could be followed-up, the melatonin treatment was stopped because their sleep problem was resolved, and in 1 child because sleep was not improved. One child developed mild generalized epilepsy 4 months after the trial started. The researchers concluded that melatonin at 5 mg taken at 6 PM was relatively safe to take in short term and significantly more effective than placebo in advancing sleep onset, dim light melatonin onset, and increasing sleep duration in elementary school children with chronic sleep onset insomnia. In the Dodge and Wilson study [2001], the investigators explored the safety and efficacy of 5 mg of melatonin administered at 8:00 PM in the treatment of sleep problems in 20 children with developmental disabilities, including cerebral palsy, autism, and mental retardation. The investigation was a randomized, double-blind, placebo-controlled, 6-week trial of melatonin versus UPDATED 6/5/2009 Melatonin, Easy Dissolve, 3 mg NF0390T PAGE 1 OF 5
2 placebo. All but 2 children fell asleep more quickly when receiving melatonin than placebo. Overall, the greater the sleep latency (time to fall asleep) was at baseline or when receiving placebo, the more pronounced was the decrease in sleep latency with melatonin. The effect of melatonin on sleep latency was significant (P<.05). The duration of sleep while receiving melatonin was significantly greater than baseline (P<.007), but was not significantly different from placebo, and no difference in the number of awakenings was noted. No side effects were reported. Eleven of 18 parents (61%) correctly identified the weeks their child received melatonin. This study suggests that melatonin can be used to reduce sleep latency in children with developmental disabilities. Adverse Side Effects The administration of melatonin is usually well tolerated, but it can be associated with mild adverse effects. Dollins et. al. using higher than normal doses of 10, 20, 40 or 80 mg in 20 healthy males found that all doses compared to placebo significantly decreased oral temperature, the number of correct responses in auditory vigilance, response latency in reaction time, and self reported vigor [Dollins et al, 1993]. Other reports include headache, transient depressive symptoms, fatigue, confusion, drowsiness, mild tremor, mild anxiety, dizziness, and abdominal cramps [Citera et al, 2000] [Dagan et al, 1998] [Dollins et al, 1993] [Jellin et al, 2004] [Nishiyama et al, 2001] [Suhner et al, 1998a] [Wagner et al, 1998]. Dagan et. al. found in a six-week treatment course with 61 DSPS patients, using 5 mg at 10 pm, that 57.4 percent reported no adverse effects, 34.4 percent reported slight daytime fatigue, and 8.2 percent reported headaches and nausea [Dagan et al, 1998]. Melatonin, its analogs, and its metabolites are not mutagenic, and melatonin possesses remarkably low acute toxicity in animals and humans [Weaver, 1997]. Interactions Melatonin may interact adversely when used in combination with medications for improving sleep. One study found a combination of melatonin and zolpidem had reports of nausea, vomiting, amnesia, and somnambulia (sleep-walking) to the point of incapacitation [Suhner et al, 1998a]. Melatonin may potentiate the anticoagulant and antiplatelet actions of medications or herbs used to modulate blood clotting [Jellin et al, 2004]. Melatonin may have the ability in diabetic patients to impair glucose utilization and increase insulin resistance [Jellin et al, 2004]. Because contraceptive drugs can elevate endogenous melatonin, concomitant use of melatonin could be associated with melatonin adverse effects [Jellin et al, 2004]. Flumazenil may inhibit the effect of melatonin [Jellin et al, 2004]. Fluvoxamine significantly inhibits the elimination of melatonin [Hartter et al, 2000]. In one study, a 17-fold higher (P<.05) area under the concentration-time curve and a 12-fold higher (P<.01) serum peak concentration of melatonin was found [Hartter et al, 2000]. Melatonin can decrease the effectiveness of Nifedipine GITS monotherapy in the modulation of blood pressure [Lusardi et al, 2000]. Lusardi et al. found in a placebo-controlled, double-blind, and cross-over study with 47 well controlled mild to moderate hypertensive patients on mg daily of Nifedipine GITS, that when 5 mg of melatonin was added nightly over 4 weeks, there was a daily average increase in systolic blood pressure of 6.5 mmhg and in diastolic blood pressure of 4.9 mmhg, with an average increase in heart rate of 3.9 beats per minute. The DBP and HR were particularly evident during the morning and the afternoon hours. Precautions / Cautions DRIVING PERFORMANCE: The impact of melatonin use on driving performance remains a central concern. One published investigation was conducted by the University of Zurich Travel Clinic, in the Institute of Social and Preventative Medicine [Suhner et al, 1998b]. Researchers investigated the effects of melatonin on driving performance parameters in 20 men and women aged years. On each testing day, subjects received 5 mg or placebo, taken at 4:30 PM. One hour later, a test series was performed consisting of a medical examination, body sway measurement, and a standardized driving computer test battery to assess attention, reaction time, power of concentration, and sensomotor coordination. Subjective sleepiness was measured on three occasions during each test session using the Stanford Sleepiness Scale questionnaire. UPDATED 6/5/2009 Melatonin, Easy Dissolve, 3 mg NF0390T PAGE 2 OF 5
3 RESULTS: In assessing the results, the investigators reported that only one of the 16 main variables of the driving computer test battery [selective attention tested by signal-detection] was significantly affected by melatonin. However, even those values were still within normal range. Subjective sleepiness was increased by melatonin, although this affect became significant only after the prolonged concentration task. Neither the medical examination nor the body sway test demonstrated signs of drug influence. CONCLUSION: The researchers concluded that overall the results of the computer test battery demonstrated no objective adverse impact of melatonin on driving performance. However, due to the increased subjective sleepiness after administration of melatonin, caution should be exercised when driving under the influence of melatonin. Melatonin may cause epileptic seizure in the susceptible. Dopamine is considered an endogenous down-regulator of seizure activity and melatonin is capable of causing a decrease in dopamine output within areas of the brain thought to participate in the control of epileptic seizure [Steward, 2001]. Melatonin is an effective treatment for biological rhythm related insomnia, but it is not necessarily an effective treatment for psychophysiologically related insomnia [Dagan et al, 1998]. Contraindications Do not use in people with seizure disorder. Do not use during pregnancy, or the breast-feeding period. Do not use with sedatives, or immuno-suppressive drugs. Do not operate a motor vehicle or machinery for 5 hours after taking this product. Pharmaceutical Commentary Melatonin is a neurohormone produced in the pineal gland located in the center of the brain and is associated with inducing a sedative effect. During conditions of dim light, special retinal photoreceptors spontaneously release norepinephrine, activating neural pathways that run to the pineal gland, through the suprachiasmatic nuclei (SCN) in the hypothalamus, resulting in pineal synthesis of melatonin, and its passive diffusive secretion into the bloodstream [Brzezinski, 1997]. However, light of sufficient intensity reaching the retinal tissues hyperpolarizes these special photoreceptors, preventing pineal melatonin synthesis [Brzezinski, 1997]. The photoreceptors mediating this process are different from the rod and cone photoreceptors that produce colour and light perception [Kavita et al, 2001]. Some blind people who evidence no pupillary light reflexes or visual perception still have light-induced suppression of melatonin synthesis [Brzezinski, 1997] [Czeisler et al, 1995]. Most aspects of physiology and behavior are time-integrated by sensitive biological clock mechanisms centered in the suprachiasmatic nuclei (SCN) of the hypothalamus, which acts on neural and endocrine pathways to regulate a variety of different circadian rhythms so that internal states vary predictably over a 24-hour cycle [Hastings, 1998]. (The word circadian is made up of two Latin roots; circa = about, and diem = day). The suprachiasmatic nuclei are comprised of approximately 10,000 neurons and if these nuclei are destroyed, the ability to express overt circadian rhythms is destroyed [Hastings, 1997] [Kline et al, 1991]. The circadian mechanisms associated with the SCN are autonomous, and individual neurons from the SCN demonstrate clock regulation that is so powerful that the rhythms of a single neuron can be recorded continuously for several weeks with only the slightest deviation from a 24 hour cycle [Hastings, 1998] [Welsh et al, 1995]. In terms of hypothalamic SCN sleep regulation, most people achieve a satisfactory sleep-wake circadian rhythm over each 24- hour day. However, due to age-related decline in endogenous melatonin synthesis, jet travel over time zones, or shift work, a discrepancy can arise between the established biological sense of time, and the actual local time. Such desynchronization causes the biological clock to impose a sleep-wake rhythm that is out of synch with local time, resulting in sleep deficits and numerous minor physiological and psychological complaints [Forger et al, 2003]. A condition of chronic desynchronization that typically requires clinical management is delayed sleep-phase syndrome (DSPS). In this condition, the person is unable to attain sleep in the common nocturnal time-frame because the SCN clock delays the sleep-phase of the sleep-wake rhythm until 2 AM to 3 AM. Clinicians observe that the sleep duration [say 7-8 hours] and quality [required sleep stages are achieved] in DSPS are considered to be normal. Thus, the point of awakening is correspondingly delayed [shifted forward by approximately 4 hours] until around 11 AM. Patients with DSPS usually find it difficult to function well if they are required to rise in the early hours of the morning. Melatonin is thought to act in at least two ways in relation to maintaining a restful sleep pattern. Firstly, melatonin is known to produce a sedative effect in animals and humans. This sedative effect is thought to stem from enhanced gammaaminobenzoic acid (GABA) receptor binding, producing an inhibitory action on the reticular activating system, which mediates wakefulness [Golombek et al, 1996] [Mignot et al, 2002] [Wang et al, 2002]. Melatonin is necessary to turn-down imposed wakefulness, but UPDATED 6/5/2009 Melatonin, Easy Dissolve, 3 mg NF0390T PAGE 3 OF 5
4 such sedation is not sufficient for the establishment of sleep. Sleep like wakefulness is imposed, but by another set of neurological properties mediated by the SCN circadian clock governing the sleep-wake rhythm. A rising melatonin plasma level commensurate with room darkness facilitates the onset of sedation, and this presumably matches a mounting SCN clock commitment to impose sleep. The second way melatonin acts to ensure a restful sleep pattern pertains to SCN clock synchronization. As the seasonal dark-light pattern varies throughout the year, the SCN clock must adapt to the way sleep requirements change in real time. Endogenous melatonin is thought to act as an entrainment agent to accomplish this adaptation [Kovacs et al, 2000] [Shantha et al, 2003] [Sharkey & Eastman, 2002]. Entrainment is the complex process of resynchronizing the biological clock with real time. Critical incremental changes in dim light timing, serve as entrainment information for re-setting the clock. The SCN neurons are able to decipher the trending darkness pattern, mirrored in the corresponding dark-mediated melatonin plasma levels. SCN neurons continuously perceive shifts in melatonin as a function of the dark-light cycle, adapting the clock imposed sleep-wake rhythm throughout the year accordingly. Desynchronization is a condition of failed adaptation and is represented in the concept of a phase-shift. In other words, the sleep-phase of the sleep-wake circadian rhythm has been shifted to another time that is out of synch with real time. Usually the sleep-phase is pushed or shifted forward, meaning sleep is postponed or delayed. The overt use of exogenous melatonin can induce entrainment to correct for desynchronization [Dagan et al, 1998] [Lewy et al, 1992] [Shantha et al, 2003] [Sharkey & Eastman, 2002]. Such entrainment may provide completely satisfactory management of jet-lag, shift work, or more challenging sleep aberrations as seen in DSPS, depression, or Alzheimer s disease. In more challenging categories, physician or pharmacist guidance may be more appropriate than self medication alone. Melatonin can entrain the free-running circadian rhythms of blind people and it has been used to treat the symptoms of circadian maladaptation associated with delayed sleep-phase syndrome [Dagan et al, 1998] [Lewy et al, 1992] [Sharkey & Eastman, 2002]. Dagan et. al. described the results of a 6-week clinical trial using 5 mg of melatonin for treating 61 DSPS patients [Dagan et al, 1998]. The mean duration of sleep before treatment was 8 hours and 21 minutes, demonstrating that delayed sleep-phase syndrome is not about the lack of sleep but rather about the timing of sleep onset. The mean pretreatment sleep onset and waking times were respectively 3:09 AM and 11:31 AM. Melatonin was administered at 10:00 PM, five hours before the average pretreatment sleep onset time. A survey of the patients was conducted between 12 and 18 months after the 6-week melatonin treatment ended. The response rate was 59 of the 61 original patients. Of this 59 patients, 54 (91.5%) reported relapse to their pretreatment sleeping patterns within one year after stopping the melatonin treatment. However, 17 (28.8%) respondents reported that their relapse occurred within one week of discontinuing melatonin. Dagan and his fellow investigators stated that their findings confirm earlier evidence that melatonin was effective in changing the sleep-wake patterns of DSPS patients. However, the finding that the new sleep patterns were not permanently retained suggests that exogenous melatonin does not cause a fundamental and permanent change in sleep regulation, thus DSPS patients may need to take melatonin regularly [Dagan et al, 1998]. Lewy and fellow investigators generated a phase-response curve (PRC) to melatonin that demonstrated circadian phase advances with melatonin administration in the late afternoon and evening, and circadian phase delays with administration in the later hours of sleep and the morning [Lewy et al, 1992]. Their observations offer some basis on how to empirically time a melatonin dose in DSPS, but also in better managing sleep problems associated with shift work and on going episodes of jet lag. UPDATED 6/5/2009 Melatonin, Easy Dissolve, 3 mg NF0390T PAGE 4 OF 5
5 References Brzezinski, A., Melatonin in humans, N Eng J Med, Jan; 16, 336(3): , 1997 Citera G., et al, The effect of melatonin in patients with fibromyalgia: a pilot study, Clin Rheumatol, 19:9-13, 2000 Coppola, G., Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a doubleblind, cross-over, placebo-controlled trial, Brain Dev, Sep; 26(6): , 2004 Czeisler, C. A., et al, Suppression of melatonin secretion in some blind patients by exposure to bright light, N Eng J Med, 332:6-11, 1995 Dagan, Y., et al, Evaluating the role of melatonin in the long-term treatment of delayed sleep phase syndrome(dsps), Chronobiol Int, 15(2): , 1998 Dodge, N.N., G.A. Wilson, Melatonin for treatment of sleep disorders in children with developmental disabilities, J Child Neurol, Aug; 16(8): , 2001 Dollins, A.B., et al, Effect of pharmacological daytime doses of melatonin on human mood and performance, Psychopharmacol, 112: , 1993 Forger, Daniel B., et al, Development and validation of computational models for mammalian circadian oscillators, J Integrative Biol, 7(4): , 2003 Forrester, M.B., Melatonin exposures reported to Texas poison centers in , Vet Hum Toxicol, Dec; 46(6): , 2004 Golombek, D.A., et al, Melatonin effects on behavior: possible mediation by central GABaergic system, Neurosci Biobehav Rev, 20: , 1996 Gupta, M., Add-on melatonin improves quality of life in epileptic children on valproate monotherapy: a randomized, double-blind, placebo-controlled trial, Epilepsy Behav, Jun; 5(3): , 2004 Gupta, M., et al, Effects of add-on melatonin administration on antioxidant enzymes in children with epilepsy taking carbamazepine monotherapy: a randomized, doubleblind, placebo-controlled trial, Epilepsia, Dec; 45(12): , 2004 Hartter, S., et al, Increased bioavailability of oral melatonin after fluvoxamine coadministration, Clin Pharmacol Ther, Jan; 67(1):1-6, 2000 Hastings, Michael, Central Clocking, Trends Neurosci, 20: , 1997 Hastings, Michael, The brain, circadian rhythms, and clock genes, BMJ, 317:1704-7, 1998 Jellin, J.M., et al, Pharmacist s Letter/Prescriber s Letter Natural Medicines Comprehensive Database, 6th ed., Stockton, CA: Therapeutic Research Faculty, 2004 Kavita, Thapan, et al, An action potential for melatonin suppression: evidence for a novel non-rod, non-cone photoreceptor system in humans, J Physiology, 535(1): , 2001 Kovacs, Jozsef, et al, Measurement of urinary melatonin: a useful tool for moniting serum melatonin after its oral administration, J Clin Endocrinology Metabolism, 85 (2): , 2000 Kline, D.C., Moore, R.E., Reppert, S.M., Suprachiasmatic Nucleus: The Mind s Clock, Oxford University Press, New York, 1991 Lane, E.A., Moss, H.B., Pharmacokinetics of metabolism in man: first pass hepatic metabolism, J Clin Endocrinol Metab, 61: , 1985 Lewy, A.J., et al, Melatonin shifts human circadian rhythms according to phase-response curve, Chronobiol Int, Oct; 9(5): ,1992 Lusardi, P., et al, Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: a 24-hour study, Br J Clin Pharmacol, May; 49(5): , 2000 Mignot, Emmanuel, et al, Sleeping with the hypothalamus: emerging therapeutic targets for sleep disorders, Nature Neurosci, Nov; 5: , 2002 Nishiyama,K., et al, Acute effects of melatonin administration on cardiovascular autonomic regulation in healthy men, Am Heart J, 141:E9, 2001 Phillips, L., R.E. Appleton, Systematic review of melatonin treatment in children with neurodevelopmental disabilities and sleep impairment, Dev Med Child Neurol, Nov, 46(11): , 2004 (Review) Shantha, M.W., et al, Melatonin phase-shifts human circadian rhythms with no evidence of changes in the duration of endogenous melatonin secretion or the24-hour production of reproductive hormones, J Clin Endocrinol Metab, 88(9): , 2003 Sharkey, Katherine M, Charmane I. Eastman, Melatonin phase shifts human circadian rhythms in a placebo-controlled simulated night-work study, Am J Physiol Regul Integr Comp Physiol, 282: , 2002 Smits, M.G., et al, Melatonin for chronic sleep onset insomnia in children: a randomized placebo-controlled trial, J Child Neurol, Feb; 16(2):86-92, 2001 Steward, L.S., Endogenous melatonin and epileptogenesis: facts and hypothesis, Int J Neurosci, Mar; 107(1-2):77-85, 2001 Suhner, A., et al, Comparative study to determine the optimal melatonin dosage form for alleviation of jetlag, Chronobiol Int, 15(2): , 1998a Suhner, A., et al, Impact of melatonin on driving performance, J Travel Med, Mar; 5(1):7-13, 1998b Wagner, J., et al, Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia, Ann Pharmacother, 32: , 1998 Waldhauser, F., et al, Bioavailability of oral melatonin in humans, Neuroendocrinology, Oct; 39(4): , 1984 Wang, F., et al, Hypnotic activity of melatonin: involvement of semicarbazide hydrochloride, blocker of synthetic enzyme for GABA, Acta Pharmacologica Sinica, Sep; 23 (9): , 2002 Weaver, D.R., Reproductive safety of melatonin: a wonder drug to wonder about, J Biol Rhythms, Dec; 12(6): , 1997 Welsh, D.K., et al, Individual neurons dissociated from rat suprachiasmatic nucleus express independently phased circadian firing rhythms, Neuron, 14: , 1995 CONCERNS? COMMENTS? CALL For more monographs go to: UPDATED 6/5/2009 Melatonin, Easy Dissolve, 3 mg NF0390T PAGE 5 OF 5
Melatonin 3 mg Sublingual Tablets
Melatonin 3 mg Sublingual Tablets Product Summary: Sublingual melatonin is used to improve the quality of sleep in those with an age-related decline in melatonin. Sublingual melatonin is also used to reestablish
More informationMOH CLINICAL PRACTICE GUIDELINES 2/2008 Prescribing of Benzodiazepines
MOH CLINICL PRCTICE GUIELINES 2/2008 Prescribing of Benzodiazepines College of Family Physicians, Singapore cademy of Medicine, Singapore Executive summary of recommendations etails of recommendations
More informationSupplements in Psychiatry: N-Acetylcysteine, Omega-3 Fatty Acids & Melatonin. March 19, 2004 David A. Graeber, MD UNM Department of Psychiatry
Supplements in Psychiatry: N-Acetylcysteine, Omega-3 Fatty Acids & Melatonin March 19, 2004 David A. Graeber, MD UNM Department of Psychiatry 1 N-Acetylcysteine = NAC NAC modulates Neurotransmitters: 1.
More informationMELATONIN FOR SLEEP DISORDERS IN CHILDREN AND ADOLESCENTS WITH NEURODEVELOPMENTAL DISORDERS SHARED CARE GUIDELINES
MELATONIN FOR SLEEP DISORDERS IN CHILDREN AND ADOLESCENTS WITH NEURODEVELOPMENTAL DISORDERS SHARED CARE GUIDELINES Version control: Version Date Main changes/comments V1 4 June 2013 First draft circulated
More informationAutism Spectrum Disorders and Comorbid Behavioral Health Symptoms
Autism Spectrum Disorders and Comorbid Behavioral Health Symptoms Cynthia King, MD Child and Adolescent Psychiatrist Associate Professor of Psychiatry UNMSOM Psychopharmacologic and Alternative Medicine
More informationINITIATING ORAL AUBAGIO (teriflunomide) THERAPY
FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been
More informationAlcohol Withdrawal Syndrome & CIWA Assessment
Alcohol Withdrawal Syndrome & CIWA Assessment Alcohol Withdrawal Syndrome is a set of symptoms that can occur when an individual reduces or stops alcoholic consumption after long periods of use. Prolonged
More informationA Healthy Life RETT SYNDROME AND SLEEP. Exercise. Sleep. Diet 1. WHY SLEEP? 4. ARE SLEEP PROBLEMS A COMMON PARENT COMPLAINT?
Diet Sleep Exercise RETT SYNDROME AND SLEEP DR. DANIEL GLAZE, MEDICAL DIRECTOR THE BLUE BIRD CIRCLE RETT CENTER A good night s sleep promotes learning, improved mood, general good health, and a better
More informationMelatonin, Circadian Rhythms, and Sleep Irina V. Zhdanova, MD, PhD * Valter Tucci
Melatonin, Circadian Rhythms, and Sleep Irina V. Zhdanova, MD, PhD * Valter Tucci Address * Department of Anatomy and Neurobiology, Boston University Medical School, 715 Albany Street R-913, Boston, MA
More informationA practical approach to circadian rhythm sleep disorders
Sleep Medicine Reviews (2008) -, -ewww.elsevier.com/locate/smrv Clinical review A practical approach to circadian rhythm sleep disorders Bjørn Bjorvatn a,b,c, *, Ståle Pallesen b,c,d a Department of Public
More informationMelatonin: Comprised by BVV
Melatonin: Melatonin is a substance produced by the pineal gland in the brain. This gland is about the size of a kernel of corn. It produces melatonin in response to low light or dark environments. Melatonin
More informationShare the important information in this Medication Guide with members of your household.
MEDICATION GUIDE BUPRENORPHINE (BUE-pre-NOR-feen) Sublingual Tablets, CIII IMPORTANT: Keep buprenorphine sublingual tablets in a secure place away from children. Accidental use by a child is a medical
More informationHeadache and Sleep Disorders 屏 東 基 督 教 醫 院 沈 秀 祝
Headache and Sleep Disorders 屏 東 基 督 教 醫 院 沈 秀 祝 Sleep Sleeping later Sleep deprivation Excessive Sleep Sleep Migraine Physiology of sleep Headache Clinical, Anatomical, and Physiologic Relationship Between
More informationAdjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.
Shared Care Guideline for Prescription and monitoring of Naltrexone Hydrochloride in alcohol dependence Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist,
More informationPaxil/Paxil-CR (paroxetine)
Generic name: Paroxetine Available strengths: 10 mg, 20 mg, 30 mg, 40 mg tablets; 10 mg/5 ml oral suspension; 12.5 mg, 25 mg, 37.5 mg controlled-release tablets (Paxil-CR) Available in generic: Yes, except
More informationAlcohol Withdrawal. Introduction. Blood Alcohol Concentration. DSM-IV Criteria/Alcohol Abuse. Pharmacologic Effects of Alcohol
Pharmacologic Effects of Alcohol Alcohol Withdrawal Kristi Theobald, Pharm.D., BCPS Therapeutics III Fall 2003 Inhibits glutamate receptor function (NMDA receptor) Inhibits excitatory neurotransmission
More informationPRODUCT MONOGRAPH. Pr PROLOPA. levodopa and benserazide combination. Capsules 50-12.5, 100-25, 200-50. Pharmaceutical standard: professed
PRODUCT MONOGRAPH Pr PROLOPA levodopa and benserazide combination Capsules 50-12.5, 100-25, 200-50 Pharmaceutical standard: professed Antiparkinson Agent Hoffmann-La Roche Limited Date of Preparation:
More informationNovartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI)
Novartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI) Highlights from Prescribing Information - the link to the full text PI is as follows: http://www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdf
More informationUniversity at Buffalo School of Pharmacy and Pharmaceutical Sciences Drug Information Response Documentation. Module Dates:
University at Buffalo School of Pharmacy and Pharmaceutical Sciences Drug Information Response Documentation Module Dates: 10/24/05-11/30/05 Preceptor Name: Dr. Tammie Lee Demler Name of Clerkship: Applied
More informationSummary of the risk management plan (RMP) for Aripiprazole Pharmathen (aripiprazole)
EMA/303592/2015 Summary of the risk management plan (RMP) for Aripiprazole Pharmathen (aripiprazole) This is a summary of the risk management plan (RMP) for Aripiprazole Pharmathen, which details the measures
More informationPrimary Care Management of Sleep Complaints in Adults
Scope Primary Care Management of Sleep Complaints in Adults (Revised 2004) This guideline is for the primary care management of non-respiratory sleep disorders in adults and follows the DSM-IV-TR classification
More informationNormal Aging versus Alzheimer Disease Drugs to treat the symptoms that are not due to old age. Leah Wright, HBSc. BSP student June 2006
Normal Aging versus Alzheimer Disease Drugs to treat the symptoms that are not due to old age. Leah Wright, HBSc. BSP student June 2006 Alzheimer Disease is a form of dementia that affects 5% of men and
More informationSeminar/Talk Calendar
Seminar/Talk Calendar Tuesday, February 3rd Dr. John Neumaier, Professor of Psychiatry and Pharmacology, University of Washington DREADDing Addiction Dr. Neumaier s laboratory is studying stress and addiction
More informationMedical Information to Support the Decisions of TUECs INTRINSIC SLEEP DISORDERS
Introduction Excessive daytime sleepiness (EDS) is a common complaint. Causes of EDS are numerous and include: o Intrinsic sleep disorders (e.g. narcolepsy, obstructive sleep apnoea/hypopnea syndrome (OSAHS)
More informationU.S. Scientific Update Aricept 23 mg Tablets. Dr. Lynn Kramer President NeuroScience Product Creation Unit Eisai Inc.
U.S. Scientific Update Aricept 23 mg Tablets Dr. Lynn Kramer President NeuroScience Product Creation Unit Eisai Inc. Unmet Need in Moderate to Severe Alzheimer s Disease (AD) Ongoing clinical deterioration
More informationTHE BACKGROUND LUMINANCE AND COLOUR TEMPERATURES INFLUENCE ON ALERTNESS AND MENTAL HEALTH
THE BACKGROUND LUMINANCE AND COLOUR TEMPERATURES INFLUENCE ON ALERTNESS AND MENTAL HEALTH T. Govén, T. Laike, B. Pendse, K. Sjöberg, 2007 1. Purpose of the study to lay down the appropriate luminance levels
More informationTrileptal (Oxcarbazepine)
Brand and Generic Names: Trileptal Tablets: 150mg, 300mg, 600mg Liquid Suspension: 300mg/5mL Generic name: oxcarbazepine What is Trileptal and what does it treat? Trileptal (Oxcarbazepine) Oxcarbazepine
More informationWhite, circular, biconvex, uncoated tablets with a score line on one side, plain on the other.
Nausicalm Cyclizine hydrochloride Ph. Eur. 50 mg Presentation White, circular, biconvex, uncoated tablets with a score line on one side, plain on the other. Uses Actions The active ingredient-cyclizine
More informationMEDICATION GUIDE WELLBUTRIN (WELL byu-trin) (bupropion hydrochloride) Tablets
MEDICATION GUIDE WELLBUTRIN (WELL byu-trin) (bupropion hydrochloride) Tablets Read this Medication Guide carefully before you start using WELLBUTRIN and each time you get a refill. There may be new information.
More informationNaltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance
Naltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance Introduction Indication/Licensing information: Naltrexone is licensed for use as an additional therapy, within
More informationMedication Guide KLONOPIN (KLON-oh-pin) (clonazepam) Tablets
Medication Guide KLONOPIN (KLON-oh-pin) (clonazepam) Tablets Read this Medication Guide before you start taking KLONOPIN and each time you get a refill. There may be new information. This information does
More information2. What Should Advocates Know About Diabetes? O
2. What Should Advocates Know About Diabetes? O ften a school district s failure to properly address the needs of a student with diabetes is due not to bad faith, but to ignorance or a lack of accurate
More informationMedication Guide EQUETRO (ē-kwĕ-trō) (carbamazepine) Extended-Release Capsules
Medication Guide EQUETRO (ē-kwĕ-trō) (carbamazepine) Extended-Release Capsules Read this Medication Guide before you start taking EQUETRO and each time you get a refill. There may be new information. This
More informationMaintenance of abstinence in alcohol dependence
Shared Care Guideline for Prescription and monitoring of Acamprosate Calcium Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist, Alcohol Services Dr Donnelly
More informationNon Medicinal: cellulose, para amino benzoic acid, silicon dioxide, vegetable grade magnesium stearate (lubricant); Gelatin capsule.
3137-9 webber naturals 6-25273-03137-9 NPN: 02245512 Class: Nutrient B50 Complex Ingredients (alphabetical) Medicinal: Biotin, choline bitartrate, vitamin B5 (d-pantothenic acid), folic acid, inositol,
More informationNursing 113. Pharmacology Principles
Nursing 113 Pharmacology Principles 1. The study of how drugs enter the body, reach the site of action, and are removed from the body is called a. pharmacotherapeutics b. pharmacology c. pharmacodynamics
More informationTreatments for Major Depression. Drug Treatments The two (2) classes of drugs that are typical antidepressants are:
Treatments for Major Depression Drug Treatments The two (2) classes of drugs that are typical antidepressants are: 1. 2. These 2 classes of drugs increase the amount of monoamine neurotransmitters through
More informationEmergency Room Treatment of Psychosis
OVERVIEW The term Lewy body dementias (LBD) represents two clinical entities dementia with Lewy bodies (DLB) and Parkinson s disease dementia (PDD). While the temporal sequence of symptoms is different
More informationEndocrine Responses to Resistance Exercise
chapter 3 Endocrine Responses to Resistance Exercise Chapter Objectives Understand basic concepts of endocrinology. Explain the physiological roles of anabolic hormones. Describe hormonal responses to
More informationMEDGUIDE SECTION. What is the most important information I should know about SEROQUEL? SEROQUEL may cause serious side effects, including:
MEDGUIDE SECTION Medication Guide SEROQUEL (SER-oh-kwell) (quetiapine fumarate) Tablets Read this Medication Guide before you start taking SEROQUEL and each time you get a refill. There may be new information.
More informationSLEEP DISTURBANCE AND PSYCHIATRIC DISORDERS
E-Resource December, 2013 SLEEP DISTURBANCE AND PSYCHIATRIC DISORDERS Between 10-18% of adults in the general population and up to 50% of adults in the primary care setting have difficulty sleeping. Sleep
More information5.07.04. Provigil Nuvigil. Provigil (modafinil) / Nuvigil (armodafinil) Description. Section: Prescription Drugs Effective Date: July 1, 2015
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.04 Subject: Provigil Nuvigil Page: 1 of 6 Last Review Date: June 19, 2015 Provigil Nuvigil Description
More information5.07.09. Aubagio. Aubagio (teriflunomide) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.09 Subject: Aubagio Page: 1 of 6 Last Review Date: December 5, 2014 Aubagio Description Aubagio (teriflunomide)
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationHormonal Oral Contraceptives: An Overview By Kelsie Court. A variety of methods of contraception are currently available, giving men and
Hormonal Oral Contraceptives: An Overview By Kelsie Court A variety of methods of contraception are currently available, giving men and women plenty of options in choosing a method suitable to his or her
More informationSummary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT Librium 10mg Hard capsule Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 10 mg of chlordiazepoxide hydrochloride. Excipients:
More informationHealing Depression Naturally
Healing Depression Naturally By Peter Bongiorno ND, LAc and Pina LoGiudice ND, LAc Directors of Inner Source Health (www.innersourcehealth.com) While everyone experiences the blues from time to time, depression
More informationBenzodiazepines: A Model for Central Nervous System (CNS) Depressants
Benzodiazepines: A Model for Central Nervous System (CNS) Depressants Objectives Summarize the basic mechanism by which benzodiazepines work in the brain. Describe two strategies for reducing and/or eliminating
More informationCholinesterase inhibitors and memantine use for Alzheimer s disease TOPIC REVIEW
Cholinesterase inhibitors and memantine use for Alzheimer s disease TOPIC REVIEW Diagnosis of Dementia : DSM-IV criteria Loss of memory and one or more other cognitive abilities Aphasia Apraxia Agnosia
More information**Form 1: - Consultant Copy** Telephone Number: Fax Number: Email: Author: Dr Bernard Udeze Pharmacist: Claire Ault Date of issue July 2011
Effective Shared Care Agreement for the treatment of Dementia in Alzheimer s Disease Donepezil tablets / orodispersible tablets (Aricept / Aricept Evess ) These forms (1 and 2) are to be completed by both
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON HYPERICUM PERFORATUM L., HERBA (WELL-ESTABLISHED MEDICINAL USE)
European Medicines Agency Evaluation of Medicines for Human Use London, 12 November 2009 Doc. Ref.: EMA/HMPC/101304/2008 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON
More informationEpilepsy 101: Getting Started
American Epilepsy Society 1 Epilepsy 101 for nurses has been developed by the American Epilepsy Society to prepare professional nurses to understand the general issues, concerns and needs of people with
More informationSee 17 for PATIENT COUNSELING INFORMATION. Revised: 3/2016 FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: ADRENAL CRISIS IN THE SETTING OF SHOCK OR
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LYSODREN safely and effectively. See full prescribing information for LYSODREN. LYSODREN (mitotane)
More informationTreatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone )
Treatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone ) Elinore F. McCance-Katz, M.D., Ph.D. Professor and Chair, Addiction Psychiatry Virginia Commonwealth University Neurobiology of Opiate
More informationPHOSPHATE-SANDOZ Tablets (High dose phosphate supplement)
1 PHOSPHATE-SANDOZ Tablets (High dose phosphate supplement) PHOSPHATE-SANDOZ PHOSPHATE-SANDOZ Tablets are a high dose phosphate supplement containing sodium phosphate monobasic. The CAS registry number
More informationMEDICATION GUIDE. Bupropion Hydrochloride (bue-proe-pee-on HYE-droe-KLOR-ide) Extended-Release Tablets, USP (SR)
MEDICATION GUIDE Bupropion Hydrochloride (bue-proe-pee-on HYE-droe-KLOR-ide) Extended-Release Tablets, USP (SR) Read this Medication Guide carefully before you start taking bupropion hydrochloride extendedrelease
More informationPhilip Moore DO, Toxicology Fellow, PinnacleHealth Toxicology Center Joanne Konick-McMahan RN MSRN, Staff RN, PinnacleHealth
Philip Moore DO, Toxicology Fellow, PinnacleHealth Toxicology Center Joanne Konick-McMahan RN MSRN, Staff RN, PinnacleHealth I. II. Background A. AWS can occur in anyone who consumes alcohol B. Risk correlates
More informationVALIUM PRODUCT MONOGRAPH. diazepam. 5 mg Tablets. Anxiolytic-sedative. Date of Revision: February 7, 2014
PRODUCT MONOGRAPH VALIUM diazepam 5 mg Tablets Anxiolytic-sedative Hoffmann-La Roche Ltd. 7070 Mississauga Road Mississauga, Ontario L5N 5M8 Date of Revision: February 7, 2014 www.rochecanada.com Submission
More informationPROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain
P a g e 1 PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain Clinical Phase 4 Study Centers Study Period 25 U.S. sites identified and reviewed by the Steering Committee and Contract
More informationDisordered sleep at night has long been
Neurology 59 Excessive daytime sleepiness in PD Excessive Daytime Sleepiness (EDS) in Parkinson s disease (PD) is an important issue that warrants serious attention because it can have adverse effects
More informationVISTARIL (hydroxyzine pamoate) Capsules and Oral Suspension
VISTARIL (hydroxyzine pamoate) Capsules and Oral Suspension DESCRIPTION Hydroxyzine pamoate is designated chemically as 1-(p-chlorobenzhydryl) 4- [2-(2-hydroxyethoxy) ethyl] diethylenediamine salt of 1,1
More informationNEW ZEALAND CONSUMER MEDICINE INFORMATION Arrow - Diazepam
NEW ZEALAND CONSUMER MEDICINE INFORMATION Arrow - Diazepam Diazepam 2mg and 5mg tablets What is in this leaflet This leaflet answers some common questions about ARROW - DIAZEPAM. It does not contain all
More information嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
More informationCOUNTY OF LOS ANGELES - DEPARTMENT OF MENTAL HEALTH OFFICE OF THE MEDICAL DIRECTOR. 3.4 PARAMETERS FOR THE USE OF ANXIOLYTIC MEDICATIONS October 2014
COUNTY OF LOS ANGELES - DEPARTMENT OF MENTAL HEALTH OFFICE OF THE MEDICAL DIRECTOR 3.4 PARAMETERS FOR THE USE OF ANXIOLYTIC MEDICATIONS October 2014 I. GENERAL CONSIDERATIONS A. Definition: Anxiolytic
More informationLow dose naltrexone as a treatment for multiple sclerosis
Low dose naltrexone as a treatment for multiple sclerosis Can I take study demonstrated that naltrexone The low dose naltrexone as a treatment for multiple sclerosis should be of naltrexone is microcrystalline
More informationUpdate and Review of Medication Assisted Treatments
Update and Review of Medication Assisted Treatments for Opiate and Alcohol Use Disorders Richard N. Whitney, MD Medical Director Addiction Services Shepherd Hill Newark, Ohio Medication Assisted Treatment
More informationInsomnia affects 1 in 3 adults every year in the U.S. and Canada.
Insomnia What is insomnia? Having insomnia means you often have trouble falling or staying asleep or going back to sleep if you awaken. Insomnia can be either a short-term or a long-term problem. Insomnia
More information1. LAMICTAL may cause a serious skin rash that may cause you to be hospitalized or even cause death.
MEDICATION GUIDE LAMICTAL (la-mik-tal) (lamotrigine) tablets LAMICTAL (lamotrigine) chewable dispersible tablets LAMICTAL ODT (lamotrigine) orally disintegrating tablets What is the most important information
More informationEFFIMET 1000 XR Metformin Hydrochloride extended release tablet
BRAND NAME: Effimet XR. THERAPEUTIC CATEGORY: Anti-Diabetic PHARMACOLOGIC CLASS: Biguanides EFFIMET 1000 XR Metformin Hydrochloride extended release tablet COMPOSITION AND PRESENTATION Composition Each
More informationHuman Clinical Study for Free Testosterone & Muscle Mass Boosting
Human Clinical Study for Free Testosterone & Muscle Mass Boosting GE Nutrients, Inc. 920 E. Orangethorpe Avenue, Suite B Anaheim, California 92801, USA Phone: +1-714-870-8723 Fax: +1-732-875-0306 Contact
More informationMelatonin prolongedrelease. (Circadin) for insomnia
Melatonin prolongedrelease tablets (Circadin) for insomnia This Medicine Update is for people who are taking, or thinking about taking, prolongedrelease melatonin. Summary Melatonin prolonged-release tablets
More informationFACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN
FACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN General Pantarhei Bioscience B.V. is an emerging specialty pharmaceutical company with a creative approach towards drug development. The Company
More informationVibramycin Capsules Doxycycline hyclate capsules USP. Vibra-Tabs Film Coated Tablets Doxycycline hyclate tablets USP
32 READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Vibramycin Capsules Doxycycline hyclate capsules USP Vibra-Tabs Film Coated Tablets Doxycycline hyclate tablets USP
More informationNaltrexone: (Vivitrol )
Naltrexone: Injectable Formulation (Vivitrol ) 1 Opioid Receptors and Alcohol Dependence 4 1. Gianoulakis C. Alcohol Health Res World. 1998;22:202-210. 2. Woodward JJ. Principles of Addiction Medicine.
More informationAlcohol Overuse and Abuse
Alcohol Overuse and Abuse ACLI Medical Section CME Meeting February 23, 2015 Daniel Z. Lieberman, MD Professor and Vice Chair Department of Psychiatry George Washington University Alcohol OVERVIEW Definitions
More informationMEDICATION GUIDE Savella (Sa-vel-la) (milnacipran HCl) Tablets
MEDICATION GUIDE Savella (Sa-vel-la) (milnacipran HCl) Tablets Savella is not used to treat depression, but it acts like medicines that are used to treat depression (antidepressants) and other psychiatric
More informationEPILEPSY. & Men s Health
EPILEPSY & Men s Health HORMONAL EFFECTS in Men with Epilepsy Does epilepsy affect hormones? Yes, epilepsy is associated with hormonal changes. For instance, experts estimate that approximately 40 percent
More informationMEDICATION GUIDE POTIGA (po-tee-ga) tablets, CV (ezogabine)
MEDICATION GUIDE POTIGA (po-tee-ga) tablets, CV (ezogabine) Read this Medication Guide before you start taking POTIGA and each time you get a refill. There may be new information. This Medication Guide
More informationVITAMIN C AND INFECTIOUS DISEASE: A REVIEW OF THE LITERATURE AND THE RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PROSPECTIVE STUDY OVER 8 YEARS
39 Chapter 3 VITAMIN C AND INFECTIOUS DISEASE: A REVIEW OF THE LITERATURE AND THE RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PROSPECTIVE STUDY OVER 8 YEARS Maxine Briggs TABLE OF CONTENTS I. Review of the
More informationSponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
More informationAbstral Prescriber and Pharmacist Guide
Abstral Prescriber and Pharmacist Guide fentanyl citrate sublingual tablets Introduction The Abstral Prescriber and Pharmacist Guide is designed to support healthcare professionals in the diagnosis of
More informationDrugs for Alcohol Dependence: Clinical Guidance and Three Way Agreement
Drugs for Alcohol Dependence: Clinical Guidance and Three Way Agreement for County Durham In partnership with the GP, the client, and the County Durham Drug and Alcohol Service December 2015 Version 1.0
More informationElements for a public summary. VI.2.1 Overview of disease epidemiology. VI.2.2 Summary of treatment benefits
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Pain is one of the most common reasons for a patient to seek medical attention. Moderate or severe intensity pain can be acute
More informationMeeting the Needs of Aging Persons. Aging in Individuals with a
Meeting the Needs of Aging Persons with Developmental Disabilities Cross Network Collaboration for Florida Aging in Individuals with a Developmental Disability Module 3 Based on ADRC training developed
More informationSativex. Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353
Sativex Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Sativex Date of issue: July 2010 Review date: July 2011 Contents 1. Introduction 1 2. What is Sativex?
More informationARTICLE #1 PLEASE RETURN AT THE END OF THE HOUR
ARTICLE #1 PLEASE RETURN AT THE END OF THE HOUR Alcoholism By Mayo Clinic staff Original Article: http://www.mayoclinic.com/health/alcoholism/ds00340 Definition Alcoholism is a chronic and often progressive
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: CSD - Suboxone Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Analgesics and Antipyretics (Opiate Partial Agonists) Client: County of San
More informationAlcohol and nicotine are widely abused substances and are often used together One study showed that 15% of patients visiting a primary care practice
Dr IM Joubert Alcohol and nicotine are widely abused substances and are often used together One study showed that 15% of patients visiting a primary care practice for any reason had either an at-risk pattern
More information1. NAME OF THE MEDICINAL PRODUCT. Impavido 10 mg capsules Impavido 50 mg capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION. 1 capsule contains:
1. NAME OF THE MEDICINAL PRODUCT Impavido 10 mg capsules Impavido 50 mg capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 capsule contains: Impavido 10 mg capsules 10 mg Miltefosine. Impavido 50 mg
More informationShared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia
Shared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia Version: 3.0 Ratified by: Medicines Committee Date ratified: 16 th November 2011 Name of originator/author: James
More informationMedical marijuana for pain and anxiety: A primer for methadone physicians. Meldon Kahan MD CPSO Methadone Prescribers Conference November 6, 2015
Medical marijuana for pain and anxiety: A primer for methadone physicians Meldon Kahan MD CPSO Methadone Prescribers Conference November 6, 2015 Conflict of interest statement No conflict of interest to
More informationSUMMARY OF RECOMMENDATIONS
SUMMARY OF RECOMMENDATIONS FOR THE LONG- TERM TREATMENT OF RLS/WED from AN IRLSSG TASK FORCE Members of the Task Force Diego Garcia- Borreguero, MD, Madrid, Spain* Richard Allen, PhD, Baltimore, MD, USA*
More informationWHAT IS DIABETES MELLITUS? CAUSES AND CONSEQUENCES. Living your life as normal as possible
WHAT IS DIABETES MELLITUS? CAUSES AND CONSEQUENCES DEDBT01954 Lilly Deutschland GmbH Werner-Reimers-Straße 2-4 61352 Bad Homburg Living your life as normal as possible www.lilly-pharma.de www.lilly-diabetes.de
More informationTeriflunomide is the active metabolite of Leflunomide, a drug employed since 1994 for the treatment of rheumatoid arthritis (Baselt, 2011).
Page 1 of 10 ANALYTE NAME AND STRUCTURE TERIFLUNOMIDE Teriflunomide TRADE NAME Aubagio CATEGORY Antimetabolite TEST CODE PURPOSE Therapeutic Drug Monitoring GENERAL RELEVANCY BACKGROUND sclerosis. The
More informationhepatolenticular degeneration (E83.0) human immunodeficiency virus [HIV] disease (B20) hypercalcemia (E83.52) hypothyroidism, acquired (E00-E03.
ICD-10-CM Codes for Mental, Behavioral and Neurodevelopmental Disorders Chapter 5 Mental, Behavioral and Neurodevelopmental disorders (F01-F99) Includes: disorders of psychological development Excludes2:
More informationMEDICATION GUIDE. TOPAMAX (TOE-PA-MAX) (topiramate) Tablets and Sprinkle Capsules
MEDICATION GUIDE TOPAMAX (TOE-PA-MAX) (topiramate) Tablets and Sprinkle Capsules Read this Medication Guide before you start taking TOPAMAX and each time you get a refill. There may be new information.
More informationFebruary 2016. page 1 / 9
February 2016 page 1 / 9 page 2 / 9 Alternative Medicines Corner Advising on this article: Nicole M. Maisch February 1, 2016 Melatonin supplementation may improve outcomes in children with atopic dermatitis
More informationDiabetes at the End of Life. Dr David Kerr MD Bournemouth Diabetes and Endocrine Centre www.b-dec.co.uk
Diabetes at the End of Life Dr David Kerr MD Bournemouth Diabetes and Endocrine Centre www.b-dec.co.uk A good way to live longer is to move to the eastern part of the English county of Dorset and take
More informationDRUGS FOR GLUCOSE MANAGEMENT AND DIABETES
Page 1 DRUGS FOR GLUCOSE MANAGEMENT AND DIABETES Drugs to know are: Actrapid HM Humulin R, L, U Penmix SUNALI MEHTA The three principal hormones produced by the pancreas are: Insulin: nutrient metabolism:
More informationPreconception Clinical Care for Women Medical Conditions
Preconception Clinical Care for Women All women of reproductive age are candidates for preconception care; however, preconception care must be tailored to meet the needs of the individual. Given that preconception
More information